ES2969534T3 - Composición sólida que comprende un compuesto del PYY y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico - Google Patents

Composición sólida que comprende un compuesto del PYY y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico Download PDF

Info

Publication number
ES2969534T3
ES2969534T3 ES20754702T ES20754702T ES2969534T3 ES 2969534 T3 ES2969534 T3 ES 2969534T3 ES 20754702 T ES20754702 T ES 20754702T ES 20754702 T ES20754702 T ES 20754702T ES 2969534 T3 ES2969534 T3 ES 2969534T3
Authority
ES
Spain
Prior art keywords
amino
compound
pyy
percent
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20754702T
Other languages
English (en)
Spanish (es)
Inventor
Andreas Vegge
Birgitte Wulff
Birgitte Nissen
Søren Østergaard
Betty Lomstein Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2969534T3 publication Critical patent/ES2969534T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES20754702T 2019-08-07 2020-08-06 Composición sólida que comprende un compuesto del PYY y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico Active ES2969534T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19190571 2019-08-07
PCT/EP2020/072137 WO2021023817A1 (en) 2019-08-07 2020-08-06 Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
ES2969534T3 true ES2969534T3 (es) 2024-05-21

Family

ID=67587403

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20754702T Active ES2969534T3 (es) 2019-08-07 2020-08-06 Composición sólida que comprende un compuesto del PYY y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico

Country Status (6)

Country Link
US (1) US20220280611A1 (cg-RX-API-DMAC7.html)
EP (1) EP4009957B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022543826A (cg-RX-API-DMAC7.html)
CN (1) CN114206375A (cg-RX-API-DMAC7.html)
ES (1) ES2969534T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021023817A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4433093A1 (en) 2021-11-15 2024-09-25 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
JP2025526148A (ja) * 2022-08-18 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 長時間作用型glp-1/グルカゴン受容体アゴニスト及びnpy2受容体アゴニストを含む組合せ治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012278A (es) * 2003-05-14 2006-02-10 Emisphere Tech Inc Composiciones para suministrar peptido yy y combatientes pyy.
GB0504857D0 (en) * 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
MX377589B (es) * 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
KR102072202B1 (ko) * 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Glp-1 펩티드의 조성물 및 그것의 제조
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
US10583172B2 (en) * 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
WO2016124687A1 (en) * 2015-02-04 2016-08-11 Novo Nordisk A/S Selective pyy compounds and uses thereof
MX392572B (es) * 2015-06-12 2025-03-24 Novo Nordisk As Compuestos del péptido yy (pyy) selectivos y sus usos.

Also Published As

Publication number Publication date
EP4009957C0 (en) 2023-10-11
JP2022543826A (ja) 2022-10-14
CN114206375A (zh) 2022-03-18
US20220280611A1 (en) 2022-09-08
WO2021023817A1 (en) 2021-02-11
EP4009957A1 (en) 2022-06-15
EP4009957B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
ES2960687T3 (es) Composiciones sólidas que comprenden un agonista del GLP-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
EP4009957B1 (en) Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
ES3041298T3 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
US20220265777A1 (en) Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
BR112013014942B1 (pt) composições sólidas para administração, e seus usos
US20220395559A1 (en) Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
US20230000949A1 (en) Solid compositions comprising a pcsk9 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
US20220323544A1 (en) Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
BR122025018208A2 (pt) Composição farmacêutica compreendendo um agonista de glp-1 e uso terapêutico da mesma
BR112020014624B1 (pt) Composição sólida compreendendo um agonista de glp-1, um sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico e um lubrificante e uso terapêutico da mesma